Viome has acquired Sōlaria Biō, adding clinically tested synbiotic formulations and medical foods to its microbiome-sequencing and personalized nutrition platform. The transaction follows Viome's earlier acquisition of Circulate Health and positions gut-targeted interventions alongside RNA-based diagnostic testing within a single commercial offering.
Key Points
- Viome adds synbiotics and medical foods through Sōlaria Biō acquisition
- Move pairs microbiome sequencing with matched gut-targeted formulations
- Second acquisition after Circulate Health expands personalized health platform
Longevity Analysis
The gut microbiome sits upstream of immune regulation, nutrient extraction, metabolic signaling and the inflammatory tone that shapes most age-related disease trajectories, which makes accurate interpretation of microbial activity more consequential than generic supplementation. Pairing transcriptomic stool analysis with formulations selected on that output moves the field away from broad-spectrum probiotics toward interventions matched to an individual's measured microbial function. The decisive variable remains clinical validation of the specific formulations and whether consumers sustain use long enough for the gut ecology and downstream immune and metabolic markers to shift.
Original published by LT Wire.